Development of a Highly Effective African Swine Fever Virus Vaccine by Deletion of the I177L Gene Results in Sterile Immunity against the Current Epidemic Eurasia Strain
Manuel V. Borca, Elizabeth Ramírez-Medina, Ediane Silva, Elizabeth A. Vuono, Ayushi Rai, Sarah Pruitt, Lauren G. Holinka, Lauro Velázquez-Salinas, James Zhu, Douglas P. Gladue
Abstract
Currently, there is no commercially available vaccine against African swine fever. Outbreaks of this disease are devastating the swine industry from Central Europe to East Asia, and they are being caused by circulating strains of African swine fever virus derived from the Georgia 2007 isolate. Here, we report the discovery of a previously uncharacterized virus gene, which when deleted completely attenuates the Georgia isolate. Importantly, animals infected with this genetically modified virus were protected from developing ASF after challenge with the virulent parental virus. Interestingly, ASFV-G-ΔI177L confers protection even at low doses (10 2 HAD 50 ) and remains completely attenuated when inoculated at high doses (10 6 HAD 50 ), demonstrating its potential as a safe vaccine candidate. At medium or higher doses (10 4 HAD 50 ), sterile immunity is achieved. Therefore, ASFV-G-ΔI177L is a novel efficacious experimental ASF vaccine protecting pigs from the epidemiologically relevant ASFV Georgia isolate.